BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Sold by Fox Run Management L.L.C.

Fox Run Management L.L.C. lessened its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 42.8% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 8,216 shares of the biotechnology company’s stock after selling 6,150 shares during the period. Fox Run Management L.L.C.’s holdings in BioMarin Pharmaceutical were worth $540,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in BMRN. Quest Partners LLC acquired a new stake in shares of BioMarin Pharmaceutical in the third quarter valued at $305,000. Advisors Asset Management Inc. boosted its holdings in BioMarin Pharmaceutical by 1.6% during the 3rd quarter. Advisors Asset Management Inc. now owns 11,451 shares of the biotechnology company’s stock valued at $805,000 after acquiring an additional 180 shares during the period. Charles Schwab Investment Management Inc. grew its position in BioMarin Pharmaceutical by 4.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,401,628 shares of the biotechnology company’s stock valued at $98,520,000 after acquiring an additional 55,699 shares in the last quarter. Swedbank AB increased its stake in BioMarin Pharmaceutical by 34.7% during the third quarter. Swedbank AB now owns 388,529 shares of the biotechnology company’s stock worth $27,310,000 after purchasing an additional 100,000 shares during the period. Finally, Daiwa Securities Group Inc. lifted its position in shares of BioMarin Pharmaceutical by 7.0% during the third quarter. Daiwa Securities Group Inc. now owns 18,006 shares of the biotechnology company’s stock worth $1,266,000 after purchasing an additional 1,185 shares in the last quarter. Hedge funds and other institutional investors own 98.71% of the company’s stock.

BioMarin Pharmaceutical Stock Down 0.6 %

BMRN opened at $71.53 on Wednesday. The stock has a market capitalization of $13.65 billion, a P/E ratio of 32.51, a price-to-earnings-growth ratio of 0.61 and a beta of 0.33. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.62 and a current ratio of 5.33. BioMarin Pharmaceutical Inc. has a one year low of $60.63 and a one year high of $94.85. The business’s 50-day simple moving average is $66.83 and its 200-day simple moving average is $67.78.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings data on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share for the quarter, beating analysts’ consensus estimates of $0.54 by $0.18. The company had revenue of $747.31 million during the quarter, compared to analysts’ expectations of $711.05 million. BioMarin Pharmaceutical had a return on equity of 9.91% and a net margin of 14.96%. Analysts anticipate that BioMarin Pharmaceutical Inc. will post 3.15 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $90.00 price objective on shares of BioMarin Pharmaceutical in a report on Thursday, February 20th. Bank of America boosted their price target on shares of BioMarin Pharmaceutical from $99.00 to $103.00 and gave the stock a “buy” rating in a research note on Thursday, February 20th. Scotiabank upped their price objective on BioMarin Pharmaceutical from $78.00 to $80.00 and gave the stock a “sector perform” rating in a research report on Thursday, February 20th. StockNews.com upgraded BioMarin Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Tuesday, March 18th. Finally, Oppenheimer upgraded BioMarin Pharmaceutical from a “market perform” rating to an “outperform” rating and set a $98.00 price target on the stock in a report on Monday, February 24th. Seven research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $94.00.

Insider Buying and Selling

In other news, CAO Erin Burkhart sold 1,295 shares of the company’s stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $71.52, for a total value of $92,618.40. Following the completion of the sale, the chief accounting officer now directly owns 16,955 shares of the company’s stock, valued at approximately $1,212,621.60. This represents a 7.10 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.85% of the stock is owned by company insiders.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.